Based on positive Phase III results for Johnson & Johnson's Zytiga abiraterone in chemotherapy-naïve, metastatic castration-resistant prostate cancer, most doctors contacted by BioCentury expect to start using the drug in earlier-stage disease, even before regulators weigh in.

FDA approved Zytiga in 2011 to treat metastatic CRPC patients who have received prior docetaxel-containing chemotherapy. Approval was based on a single Phase III trial in which Zytiga plus prednisone improved OS by 3.9 months vs. placebo plus prednisone (14.8 months vs. 10.9 months; HR=0.65; p<0.001).